Eric Meskimen Selected Research

Pain (Aches)

1/2022

Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric Meskimen Research Topics

Disease

3	Atopic Dermatitis (Atopic Eczema) 07/2023 - 01/2022
2	Eczema 01/2023 - 01/2022
1	Herpes Simplex 01/2022
1	Human Influenza (Influenza) 01/2022
1	Nasopharyngitis 01/2022
1	Pain (Aches) 01/2022
1	Headache (Headaches) 01/2022

Drug/Important Bio-Agent (IBA)

2	lebrikizumabIBA 07/2023 - 01/2023
1	Immunoglobulin A (IgA)IBA 01/2023
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022
1	baricitinibIBA 01/2022
1	Janus KinasesIBA 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022

Therapy/Procedure

1	Therapeutics 01/2022
1	Contraindications 01/2022